Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | DNA |
Clinical data | |
Other names | GX-19N |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.[1][2][3][4]
It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.[5]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|